Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

44.45 -2.05 (-4.41%)
Streaming Delayed Price Updated: 2:55 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share. 
Via Benzinga
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares... 
Via Benzinga
Where Protagonist Therapeutics Stands With Analysts
Via Benzinga
Chart Of The Day: Protagonist Therapeutics - Wide Opinions
Via Talk Markets
Protagonist Therapeutics Inc. (NASDAQ: PTGX) is a Stock Spotlight on 6/1
Via Investor Brand Network
US Stocks Mixed; Dow Falls Over 50 Points
U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.19% to 34,341.91 while the NASDAQ rose 0.28%... 
Via Benzinga
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of
Via ACCESSWIRE
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
Via ACCESSWIRE
Protagonist Therapeutics: Q1 Earnings Insights
Via Benzinga
4 Analysts Have This to Say About Protagonist Therapeutics
Via Benzinga
Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study
Via Benzinga
Why Protagonist Therapeutics Shares Are Trading Higher Today
Via Benzinga
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Via ACCESSWIRE
Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment
Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of  
Via Benzinga
Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm
The company is targeting psoriasis with a first-ever mechanism that could rival leaders. 
Via Investor's Business Daily
Why Shares of Protagonist Therapeutics Rose This Week
The company's lead pipeline candidate is making news. 
Via The Motley Fool
Why Protagonist Therapeutics Shares Are Nosediving
Protagonist Therapeutics Inc (NASDAQ: PTGX) shares are trading lower by 9.68% to $19.46 Wednesday morning after the company announced pricing of a $100 million public offering of shares of common... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
Via ACCESSWIRE
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
Via ACCESSWIRE
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
Via ACCESSWIRE
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Top 5 Health Care Stocks That May Collapse In February
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Protagonist Therapeutics Earnings Perspective: Return On Capital Employed
Protagonist Therapeutics (NASDAQ:PTGX) brought in sales totaling $859 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 96.07%, resulting in a loss of $41.04... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.